BRIEF

on Ondine Biomedical Inc (LON:OBIMF)

Ondine Biomedical Inc Reveals Potential Key Source of Surgical Infections

A new study, published in Science Translational Medicine, indicates that a significant portion of surgical site infections (SSIs) in spine surgery patients originates from their own nasal, skin, or gut bacteria. This research, conducted by the University of Washington School of Medicine, found that 86% of SSIs are linked to bacteria already present in patients before their surgery. Additionally, these infections are showing considerable resistance to conventional antibiotics, with a 59% resistance rate observed. This highlights a growing challenge in managing post-operative complications.

The study underlines the importance of nasal decolonization to reduce SSIs, particularly in surgeries involving high-risk areas such as the spine. It also emphasizes the effectiveness of new treatments such as Ondine Biomedical Inc.'s Steriwave®, a light-activated antimicrobial technology. Unlike traditional methods, Steriwave® offers immediate effectiveness without contributing to antimicrobial resistance. This development could potentially transform pre-surgical preparations and significantly decrease the incidence of SSIs.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Ondine Biomedical Inc news